University of Geneva spinout ABCDx has raised an undisclosed amount in its first funding round.
ABCDx, a Switzerland-based diagnostic products spinout from University of Geneva, raised an undisclosed amount in seed funding today from Geneva-based private investors.
Founded in 2014, ABCDx is working on blood biomarker technologies that enable faster and more cost-effective decisions about treatment for brain injuries and stroke.
The spinout is initially focusing on enabling early decision-making to ensure patients receive life-saving drugs in time. Longer-term, the spinout hopes to adapt its technology to determine whether a patient is suitable for new neuroprotective therapies.
The money will go help ABCDx to launch clinical trials, establish manufacturing and distribution channels and file for regulatory approval of a first product in the EU later this year.
The company was co-founded by Jean-Charles Sanchez, head of the Translational Biomarker Group and director of the Proteomics Core Facility at Geneva’s Faculty of Medicine.
Sanchez co-founded ABCDx with Joan Montaner, a neurologist and director of the Neurovascular Research Laboratory at Vall d’Hebron Research Institute and Vall d’Hebron Hospital in Barcelona.
The two researchers were joined by Alan Cookson, who previously led several commercialisation projects from University of Geneva.
Sanchez said: “ABCDx has assembled a group of outstanding professionals and strong partners who together will bring to the market technologies conceived and created by innovative research at University of Geneva and at Vall d’Hebron Institute of Research.
“I am proud that this academic research is now contributing to the creation of new jobs and inward investment to the Geneva area. These technologies will enable many more patients to benefit from best-in-class care for serious and debilitating brain illnesses.”
